DIPARTIMENT TAS-SAĦĦA DEPARTMENT OF HEALTH
MALTA

L-Uffiċċju tal-Uffiċjal Mediku Ewlieni *Office of the Chief Medical Officer*

DH CIRCULAR No. 55/2014
DH 611/2014

11 February 2014

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Natalizumab 20mg/mL Infusion

Natalizumab 20mg/mL infusion has been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

Natalizumab is a recombinant humanized anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology.

Natalizumab has been approved as a single disease modifying therapy in rapidly evolving severe relapsing remitting Multiple Sclerosis (RRMS).

Natalizumab 20mg/mL infusion is protocol-regulated with protocol 251 (attached) and can be prescribed by Consultant Neurologists.

Natalizumab 20mg/mL infusion has been procured through the Central Procurement and Supplies Unit and is now available for use as per protocol.

Thank you

For your attention, please

Dr. Neville Calleja
Acting Chief Medical Officer

"PALAZZO CASTELLANIA" 15, MERCHANTS STREET, VALLETTA, VLT 03
Tel. Nos. +00356 21224071/ 2299 2232 **Fax no. +00356 2299 2663**
e-mail: **cmo.mhec@gov.mt**

251

Natalizumab 20mg/mL Infusion

Prescriber Criteria: Consultant Neurologist

In-patient use:

1. Multiple Sclerosis

As a single-disease modifying therapy in rapidly evolving severe relapsing-remitting multiple sclerosis (RRMS).

RRMS is defined by two or more disabling relapses in one year, and with one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

Duration of Approval:
12 months